News

Under the agreement, Zubsolv will be given preferred, Tier 2 brand status on UHG commercial employer and individual formularies managed by OptumRx for the maintenance treatment of opioid

The trial, which evaluated the efficacy of two dose regimens of mepolizumab, also met its primary endpoint of reduction in the frequency of exacerbations. Throughout the trial, patients

ND0612 is being developed for continuous subcutaneous administration through a patch pump and is designed to provide steady levodopa blood levels for the treatment of PD. The company

Under the deal, Medinet will license its new cell therapy technology to TC Biopharm for clinical development in the UK and Europe. The deal and subsequent commercialization is

UCB’s research arm UCB NewMedicines has used a new approach to identify small molecules modulators of a biological pathway, for which parenterally administered biologic therapies have proven highly

The product was determined to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Naloxone Hydrochloride Injection 0.4mg/mL, of Hospira. The injection is indicated for the

The patent, titled ‘Methods and Compositions for Oral Administration of Exenatide’, covers oral exenatide compositions made using Oramed’s proprietary technology, including its ORMD-0901 oral exenatide capsule. The company

DME occurs due to fluid leakage into the area of the retina. The sight-threatening condition occurs in type 1 and type 2 diabetes patients. ThromboGenics’ new biotherapeutics are

Under the terms of the license agreement, Access will receive an upfront licensing fee and double digit royalties on net sales of MuGard in the licensed territory. MuGard